Shanghai based bio-technology company Kechwo Pharma rasied $45 million in a series C round funding led by Decheng Capital and followed by Qiming VC, Sherpahp Capital, and Grains Valley VC. The investment wil be used to promote clinical research of durg, apply for IPO in America and US, and enrich R&D piplline.
Established in 2014, Kechwo Pharma focuses on developing best-in-class innovative drugs. Its main businesses include self-developed R&D pipeline and research on the inhibitor of MEK—HL085. It aims to provide new solutions to cancer treatment.
South Africa Today